# A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Source: https://onco.cc/trials/nct04489771/  
OnCo record `nct04489771` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Belzutifan in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) is a phase 2 interventional study registered as NCT04489771 by Merck Sharp & Dohme LLC, with 154 participants enrolled, started 2020-09-13 and due to reach its primary completion in 2023-02-10. Interventions recorded: Belzutifan. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04489771
- Phase: 2
- Setting: Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT04489771: https://clinicaltrials.gov/study/NCT04489771

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04489771.json